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The paper deals with the analysis of literary data on the tumor cell heterogeneity. Phenotypic, genetic and epigenetic mechanisms 
of heterogeneity are considered. The heterogeneity of metastasis is considered too. The importance for the biology of populations 
of tumor cells and the sensitivity of tumors to therapeutic treatment are discussed.
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INTRODUCTION
Subject or system is called heterogeneous, if it con-
sists of numerous varying units/components, which of-
ten cannot be easily sorted or divided. The term “tumor 
heterogeneity” supposes the existence of numerous 
differences between cells in tumor, cells of primary 
tumor and metastases, cells of particular metastases 
of the same tumor [1]. In 1977, the respected journal 
“Cancer Research” didn’t take in print the article, 
authors of which, having obtained and characterized 
4 different subpopulations of tumor cells (TC) from 
one random mouse mammary tumor, had stated that 
these data were the evidence of tumor heterogeneity, 
and that such heterogeneity was the common phe-
nomenon. The editors have rejected the article and 
stated that tumor monoclonality is a notorious fact 
[2]. At the present time it was shown that the majority 
of tumors possess variability in wide range of mor-
phological and functional characteristics. It was also 
defined that heterogeneity (pleomorphism) of TC af-
fects phenotypic, genetic and epigenetic features. 
While tumor’s progression, its cells undergo number 
of various changes [2, 3]. At the same time, series 
of fundamental questions concerning the causes 
of tumor heterogeneity, mechanisms of its forma-
tion, significance of this phenomenon for evolution 
of TC population and development of cancer, remain 
open-ended. TC heterogeneity needs further study 
and analysis from the position of clinical oncology — 
for improving of diagnosis and treatment methods. The 
accumulated information in this field of study is like 
a bowl, in which incomparable terms are melting and 
new concepts are maturing.
The aim of this paper is generalization and 
analysis of data on manifestation forms, causes and 
mechanisms of formation of TC heterogeneity as well 
as points of view on this problem, ideas and concepts 
from the positions of diagnosis and treatment optimi-
zation of cancer patients.
PHENOTYPIC TC HETEROGENEITY: 
PHENOMENOLOGY, POSSIBLE CAUSES 
AND BIOLOGICAL VALUE
There are following forms of heterogeneity of tu-
mors: intertumoral heterogeneity, when different (pri-
marily multiple) tumors in the same organ have differ-
ent phenotype; intratumoral heterogeneity supposes 
that every particular tumor consists of phenotypically 
and functionally heterogeneous TC with unequal be-
havior [3]. Inasmuch development of primary multiple 
tumors is quite rare phenomenon, the main corpus 
of studies on problem are devoted to the intratumoral 
heterogeneity; in our review we also confine ourselves 
to inquiry into mentioned phenomenon only.
If we catalogue defined in various researches pa-
rameters of tumor heterogeneity, it becomes obvious 
that intensity of the latter depends on etiology of tumor, 
its histogenesis, localization in organ. Heterogeneity 
is typical for both actually TC and components (cellular 
and noncellular) of tumor microenvironment; in other 
words, parenchyma, and tumor stroma also may 
be heterogeneous. According to the publications of the 
past years, TC of one neoplasm may differ both by the 
morphological (degree of differentiation, sizes, form, 
number of nucleus, cytochemical features, karyotype, 
etc.) and by functional characteristics (morphogenetic 
reactions, level of proliferation, cell-cell interaction, 
mobility, invasiveness, inclination to metastasis, 
sensitivity to inducers of apoptosis, chemothera-
peutic agents, and immunotherapy). Heterogeneity 
of TC is described by composition of cellular mem-
branes; its antigenicity; spectrum of markers of cel-
lular surface, including receptors of growth factors; 
by activity of signaling pathways, which are controlling 
proliferation, cellular cycle, DNA reparation, apoptosis, 
functional response of cells to changes of extracellular 
environment [2–5].
The parameters of TC growth in vitro and tumori-
genicity in vivo essentially vary (including amount 
of injected cells, necessary for generating of tumors; 
latent period and speed of growth of the last) as well 
as sensitivity to non-specific reactions of antitumor 
immunity and ability of induction of the host’s specific 
immune response. At the same time, changes of the 
age and hormonal status of host’s organism influence 
the TC differences [2, 3, 6, 7].
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Clonal TC populations are also heterogeneous. 
It is shown that by the injection of each TC clone in the 
athymic mice the histologically different tumors may 
grow. Such heterogeneity is considered to occur 
mostly in result of phenotypic plasticity and differ-
ent differentiation of stem TC under the influence 
of micromedia signals and, probably, some stochas-
tic cell-autonomous mechanisms. Relative impact 
upon heterogeneity of hereditary and non-hereditary 
mechanisms is still not clear [8].
Neoplasms or their various segments may also 
differ by composition of extracellular matrix, cellular 
and noncellular components of conjunctive tissue 
(tumor’s stroma); by quantity and types of immune 
system cells infiltrating tumor parenchyma; degree 
of vascularization (both by blood and lymphatic ves-
sels), by metabolic features of microenvironment [9]. 
In other words, even in one tumor TC get different 
signals of microenvironment, which may change phe-
notype of formerly similar cells [10, 11].
At the same time, it was shown that together with 
phenotypic differences, which originate as response 
to changes of environment (TC micromedia), het-
erogeneity of TC even in the presence of obviously 
homogenous microenvironment is also possible. For 
example, genetically homogenous lines of TC may 
manifest morphological heterogeneity (combination 
of circular, unable to move epithelioid cells and mobile 
fibroblast-like cells, which may be detected both in vi-
tro and in vivo), that is the result of different mutually 
exclusive and interconvertible activation of G-proteins 
Rac and Rho [12]. The variability of TC of different 
primary tumors of the same organ, as well as of each 
individual tumor, doesn’t exhaust all aspects of tumor 
heterogeneity.
Taking into consideration above-stated informa-
tion, the following questions are of current importance: 
a) what is clonal relationship between primary and 
metastatic tumors: whether cells of metastases are di-
rect derivatives of clones of developed primary tumors 
or they deviate in the early stages of tumor evolution?; 
b) what is stage of heterogeneity of metastatic tumors 
compared to primary, whether they are more or less 
clonally heterogeneous?
There are 2 main concepts of origin of TC heteroge-
neity: different subtypes of TC originate from different 
stem cells (concept of stem cell); different subtypes 
of TC originate as the result of unmatched genetic and/
or epigenetic changes of stem (target) cell (concept 
of clonal evolution). Each of these concepts is being 
studied for a long time. Almendro et al. [10] consider 
that despite concepts of stem cell and clonal evolution 
(phenotypic plasticity) have lot of similarities, they are 
mutually exclusive as fundamentally different. How-
ever, according to the view of number of researchers, 
the detected cellular and molecular mechanisms are 
not mutually exclusive and may act together. When 
heterogeneity of certain tumors is forming, both con-
cepts (or each of them) may be fair within certain de-
gree. Even if majority of TC in some (or many?) tumors 
are not able to support proliferation and, thus, may 
be identified as non-stem, the compartment of stem 
cell must be phenotypically different and plastic [11].
It is also important to mention that epithelial-mes-
enchymal transition refers to the complex molecular 
and cellular programs, which are defying features 
of heterogeneity and differentiation (intercellular ad-
hesion, apico-basal polarity or its absence, absence 
of mobility) of epithelial cells as well as acquisition 
by them the mesenchymal functions (mobility, inva-
siveness, increase of resistance to apoptosis). The last 
at large is analyzed in reviews [13–15] which interested 
reader is being referred to.
In addition, information about synchronic change 
in vivo of some heterogeneous features of TC, which 
have absolutely different molecular basis, and about 
coincidence of spectrum of such features at antitumor 
impacts of different origin, is being accumulated bit 
by bit. So, simultaneously several features, which are 
defying resistance of TC to cytotoxic effectors of innate 
immunity, inherent to malignant (especially metastatic) 
phenotype of cells of many tumors. This secretion 
of prostaglandin Е2 (causes the suppression of ac-
tivity of natural killers, T-lymphocytes, neutrophils) 
and activation of mechanisms of catabolism Н2О2/
superoxide radicals, in particular, catalases and redox 
cycle of glutathione (provides protection of products 
of “oxygen explosion” of macrophages, neutrophils) 
[16]. At the same time, activation of glutathione sys-
tem refers to the characteristics, heterogeneously 
expressed in population of TC in process of formation 
of drug resistance, in particular, to alkylating agents 
or cisplatin [17]. The examined examples illustrate the 
idea that heterogeneity of TC is the reflection of their 
natural selection by many properties, connected with 
survival in vivo. The acquired in organism resistance 
of TC to its defense reactions, relative resistance 
to hypoxia, resistance to radial and drug (including 
targeted) therapy are connected with different mecha-
nisms, but as phenomena, which are conditioned 
by selection, have common biological nature. Hetero-
geneity of tumor is necessary condition of opportunity 
of such selection.
So, at present time there are no doubts that tumors 
are not static neoplasms. They start from genetically 
normal cell and end with forming of population, which 
consists of billions of TC, which have formed multitude 
of cellular phenotypes. The presence of many interac-
tive subpopulations (both TC and cells of microenvi-
ronment) forms the basis of phenomenon “progres-
sion, dissemination and colonization of tumor”, when 
during the time the tumor undergoes heterogeneous 
changes of its properties. It is obvious that knowledge 
of features of particular clones of TC is not enough 
for prediction of tumor’s behavior as a whole [18]. 
It is amazing that despite the apparent heterogeneity 
of tumors, they often remain relatively stable during the 
development from localized form to metastases and 
even to the last stage of disease [19, 20].
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MOLECULAR MECHANISMS OF TUMOR 
HETEROGENEITY
Mechanisms of diversification of TC may be similar 
(or identical) to the normal diversification in embryonic 
and postembryonic periods of organism development. 
As it was stated above, many researchers think that one 
of the basic causes of heterogeneity of TC population 
is high changeability. The last one is connected at least 
with 3 mechanisms: with increase of frequency of true 
genetic changes, which are fixed in line of cellular 
generations (genetic/genome instability); with signifi-
cant increase of probability of origin of TC epigenetic 
changes, which may result in suppression of expres-
sion of one genes and/or intensification of expres-
sion of others; with presence of stochastic variability 
of expression of homological proteins in particular 
genetically similar cells at the same conditions of en-
vironment (Elowitz genetic noise) [21].
Genetic instability (GI) mainly includes 2 types 
of abnormalities: gene mutations (mutation instabil-
ity, which is linked with changes in consequence 
of DNA nucleotides) and rebuildings of chromosomes 
(chromosomal instability, which originates from their 
fallacious rearrangements). The structure and number 
of mutations and changes of chromosomes during 
the time are changing in TC compared with normal 
cells [22]. In some human TC were described also 
other forms of GI, in particular, microsatellite instabil-
ity, which is characterized by increase or decrease 
of oligonucleotide repeats, existing in microsatellite 
sequence of genome [23, 24], as well as kind of GI, 
for which the increase of frequencies of base pair 
is typical [25]. In TC and normal tissue are observed 
differences between microsatellites of the same locus. 
Destabilization of microsatellite loci, apparently, is not 
being direct cause of malignization; however, it may 
be sensitive marker of mutator phenotype, manifesta-
tion of GI and one of the features of TC heterogeneity.
GI is characteristic feature of almost all human TC, 
but in which stage of tumor development it occurs, and 
what its molecular base in every certain neoplasm is, 
are the questions, which we are only starting to answer. 
In basis of GI origin underlie 4 main types of abnor-
malities — decrease of accuracy of DNA replication 
and segregation of chromosomes during mitosis; 
abnormality in systems of reparation of damaged DNA 
or mistakes of its replication; weakening of cellular 
cycle control — activation of checkpoints, what results 
in that cell with impaired DNA or chromosomal changes 
continues to divide and multiply anomalous population; 
weakening of induction of apoptosis that results in that 
cells with genetic abnormalities are not being elimi-
nated from population. All above-described abnor-
malities one way or another are linked with mutations 
and inactivation of function of antioncogenes — tumor 
suppressors. In 1977 Kinzler and Vogelstein have 
grouped these genes in 2 classes: “caretakers” and 
“gatekeepers” [26]. Products of genes-gatekeepers 
are functioning in system of control, which prohibits 
cell proliferation with different (exactly genetic) ab-
normalities. Genes-caretakers are coding products, 
which take part in DNA reparation, stabilizing genome 
in that way. Some tumor suppressors (р53, BRCA1, 
ATM, CHK2 and others) accomplish both functions 
[27]. At presence of mutation in gene-caretaker there 
is a high probability of mutation also in gene-caretaker 
[28]. In 3–31% of sporadic human tumors in genes-
caretakers are found one or more mutations. Quite 
wide spacing of data may be connected with differ-
ences in methods, which were used for identification 
of mutations [29].
In sporadic human tumors chromosomal instabil-
ity is the basic form of GI; for many hereditary tumors 
mutations, in particular, in genes of different systems 
of DNA reparation (DNA breaks — BRCA1/2, unpaired 
bases MSH2,3,6, MLH1, PMS2, excisional — XP A-G) 
are typical. Today 2 hypothetic models of GI are ac-
cepted. First of them — mutational model, which 
states that GI occurs in pretumor states and stimulates 
development of tumor by increase of level of sponta-
neous mutations. The above-mentioned identification 
of mutations in genes of DNA reparation at hereditary 
forms of cancer provides strong support of this hy-
pothesis. According to the second model the main role 
in development of tumor plays induced by oncogenes 
(RAS, BCR/ABL) stressful replication of DNA [29]. 
Impairment of correct segregation of chromosomes 
may occur as the result of change of quantity and 
structure of centrosomes or centers of organization 
of microtubules. These changes are the result of RAS 
activation and inactivation of tumor suppressors р53, 
АРС, BRCA1.
The process of DNA replication in fact puts cell 
in risk of mutations. Many genes of DNA repara-
tion system and genes, coding enzymes of matrix 
synthesis of nucleic acids, are called mutator genes 
(genes-mutators). Impairment of functioning and 
coordination of expression of genes of nucleotides 
metabolism brings to mutator phenotype, the same 
way as impairments of functioning of recombination 
system, transcription, control of chromatin structure; 
enzyme systems, which control segregation of chro-
mosomes and number of copies of individual genes; 
systems, which take part in synthesis of endogenous 
mutagens [30].
So, finally GI is linked with changes of oncogenes 
and tumor suppressors. However, as it may be con-
cluded from the researches, conducted on the wide 
spectrum of human tumors, not many of tumors are 
mutated, deleted and/or amplified in sporadic neo-
plasms with high frequency [31–34]. To the most “uni-
versal” are referred suppressors р53, INK4a, PTEN, 
Rb, genes CKI (cyclin-dependent kinases inhibitors), 
oncogenes RAS and EGFR (two forms of receptors 
of epidermal growth factor) [35]. These data support 
point of view that insignificant population of TC may 
potentially provide growth of the whole tumor mass, 
actively supporting heterogeneity of TC inside tumor 
[4]. The detection of interactions between genetically 
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heterogeneous TC may become basis for the novel 
methods of therapeutic intervention.
The human genome is dynamic: according 
to the calculations, during the day in every cell may 
be realized over 20 000 damages of DNA and over 
10 000 mistakes of replication. Number of proteins, 
which participate in replicative processes of human 
cell DNA, is unknown. Researches on the yeasts have 
showed that support of genetic stability is provided 
by more than 100 genes [32]. Even if mutagens are not 
performed in environment, mutations occur spontane-
ously with approximate speed 10–6 mutations on gene 
during cellular cycle.
During human life every particular gene may un-
dergo approximately 1010 different mutations. It results 
in mutations are being found in the whole genome, 
including genes, which support genetic instability. 
From this point of view, problem of malignant tumors 
consists not in the question, why they occur, but why 
they, from the one side, occur so rarely, and, from the 
other side, are saved as relatively stable populations 
[30, 36].
Epigenetic (Eg) are called hereditary changes 
in gene expression, which are not linked with qualita-
tive changes in DNA sequences [37, 38]. Genome 
of eukaryotes is assembled in chromatin-structural 
complex. Changes of structure of this complex as well 
as modification of chromatin by non-chromatin pro-
teins may influence the expression of particular genes, 
be the cause of the activation and/or inhibition of dif-
ferent signaling and metabolic pathways. Genetic 
and Eg mechanisms are combined and interact in all 
stages of tumor development. Eg aberrations, in con-
trast to genetic mutations, are potentially reversible; 
it is possible to renew their normal state. Eg heteroge-
neity is considered to be key element in progression 
of tumor, especially in conditions of unfavorable for the 
last actions, inasmuch it provides population of TC with 
necessary for successful selection heterogeneity, 
complicity and stability. In particular, acquired drug 
resistance of TC is connected mainly with Eg mecha-
nisms. That is why regulators of the last ones are po-
tential targets for new therapy compositions [39, 40].
Eg heterogeneity realizes through 3 individual 
mutually reinforcing mechanisms: changes of DNA 
methylation; posttranslational modifications of core 
histones; expression of RNA, which are not coding 
the protein (micro-RNA and small interfering RNA — 
miRNA). Besides the direct effect on the nuclear 
processes (such as transcriptional activity) of DNA 
methylation and modification of histones play also 
key role in regulation of chromatin structure and 
expression of genetic information [41, 42], in normal 
development and support of cellular homeostasis, 
eliminate activity of repeated elements of DNA, inac-
tivate X-chromosome in women [43].
The level of DNA methylation of normal cells is not 
inherited from parental gametes, but is eliminated 
individually in process of embryogenesis. Changes 
of DNA methylation in TC are characterized by hy-
permethylation of promoters of individual genes and 
common hypomethylation of genome compared 
with normal cell. In all without exception investigated 
tumors was detected such disbalance. By number 
of hypermethylated CpG-islands individual tumors 
may significantly differ. Along with common for several 
types of tumor hypermethylated sections of DNA, 
are also detected such sections that are hyper-
methylated only in one type, i.e. are tumor-specific. 
Significant heterogeneity of TC by hypermethylation 
is described: out of 45000 CpG-islands, which exist 
in human genome, in particular tumors may be from 
0 to 4500 hypermethylated (600 in average). Quite 
typical for TC is hypermethylation of tumor suppres-
sors and genes of DNA reparation system (first of all 
p16INC4A,as well as Rb, р53, MLH1). But even in those 
cases, when hypermethylated segments are not as-
sociated with genes, involved in GI, aberrant mutilation 
1–10% of CpG-islands in cell may cause phenotypic 
heterogeneity by the number of signs. During the last 
years, progress in discovering nature and role of mech-
anisms, involved in hypermethylation of DNA in cancer 
genesis, is going fast. Content of genome methyl-
cytosine in TC decreases from 4% in normal tissues 
to 2–3%, however it is discovered not in all tumors. 
Precise genome localizations of hypermethylation 
remain the subject of studies [44]. Despite majority 
of publications reports that hypomethylation is found 
in repeated elements, it doesn’t provide us with final 
answer to the question, which stage it originates in and 
which role plays in carcinogenesis, inasmuch there are 
differences between various classes of repeated ele-
ments. Lots of researchers think that hypomethylation 
occurs in the early stage of transformation [45], other 
connect it with later stages of tumor development. 
Hypomethylation of repeated elements may contribute 
GI, providing plasticity and advantage of TC growth, 
and is potential target of therapy [44].
Important Eg mechanism, which regulates struc-
ture of chromatin and genes expression, is modifi-
cation of histones. The main classes of enzymes, 
participating in these rearrangements, are ferments 
of chromatin remodeling and histone modifiers. Such 
posttranslational covalent modifications of histones 
as acetylation, methylation, phosphorylation, ubiq-
uitination, sumoylation, biotinylation and ADP-ribo-
sylation are mostly characterized. Despite interaction 
between different modifications of histones is still not 
defined, many of them contribute the development 
of different forms of human cancer (“histone onco-
modifications”) [46]. For example, acetyltransferase 
of histones Tip60 doesn’t influence directly (like tumor 
suppressors or oncogenes), but makes easier the 
actions of other proteins, because it is transcriptional 
co-activator [47, 48]. Its involvement in expression 
of series of genes, which are regulated by transcrip-
tion factor NF-κB, was described [49]. The last one 
is activated by many agonists (proinflammatory cyto-
kines, T- and B-cell mitogens, products of life activity 
and structural components of bacteria, viral proteins, 
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double-stranded RNA, heat shock proteins and oth-
ers), as well as by physical and chemical stresses, 
including effect of ionizing radiation and chemothera-
peutic drugs [50, 51]. Activated factors of NF-κB fam-
ily regulate transcription of over 400 genes, involved 
in immunoregulation, inflammatory, regulation of pro-
liferation and apoptosis, growth and dissemination 
of tumors (in particular, also suppressor gene of me-
tastasis KAI1). The same factor regulates chemo- and 
radioresistance in different TC. From mentioned list 
it is clear that variability of effects of NF-κB activa-
tion, which is mediated with acetyltransferase Tip60, 
may cause phenotypic heterogeneity of TC by wide 
spectrum of features [52]. Acetylation/deacetylation 
modulates expression of genes, involved in progres-
sion of tumor in process of TC selection. For example, 
hypoxia (one of the factors, which cause heterogene-
ity of TC) induces expression and activity of histone 
deacetylase, which in its turn regulates expression 
of E-cadherin — suppressor protein, which is control-
ling signaling pathway β-catenin/Cdk/pRb. The loss 
of expression of E-cadherin breaks processes of ad-
hesion, causes epithelial invasion, which is necessary 
for the first stage of metastasis [53].
One more important regulator of heterogene-
ity of tumor is miRNA, which play important role 
in support of genome integrity, in division of cells, 
support and differentiation of stem cells (embryonic 
and mature), in carcinogenesis, migration of TC and 
metastasis. This list continues growing. On the series 
of objects of the research is showed that tumor often 
avoids regulation, mediated with miRNA; repression 
of miRNA is associated with increasing of tumorigenic-
ity of TC. Each miRNa is able to regulate expression 
of more quantity of targeted genes. In contrast, one 
gene may be regulated by many miRNA that may cause 
cells heterogeneity. Understanding of level of regula-
tion with the help of miRNA may essentially deepen 
understanding of tumor biology, in particular, prob-
lems of TC heterogeneity. MiRNA may be perspective 
targets of antitumor therapy [54].
Taking into account that epigenetic mechanisms 
are in the center of many manifestations of phenotypic 
variability, it is probable that understanding and manip-
ulation with epigenome promises much in prophylaxis 
and treatment of malignant tumors [3].
Heterogeneity of cells occur naturally and inevitably 
also from “noise” processes — stochasticity in genes 
expression, that results in production of different le-
vels of certain proteins in every moment in genetically 
similar cells. Stochasticity in expression of genes de-
termines essential variations of phenotypes in popula-
tion. Majority of the researches of this phenomenon 
was conducted in populations of microorganisms, 
however, in 2006, at measurement of level of different 
proteins in genetically similar human cells was no-
ticed 15–30% abmodality in particular cells. “Genetic 
noises” launch series of useful physiological mecha-
nisms of regulation, cellular differentiation, participate 
in transfer or blockage of biological signals, coordinat-
ing expression of big variety of genes due to inequality 
of levels of synthesis of appropriate proteins, variability 
of length of its life and dissemination in cell [55, 56]. 
Ideal methodology of research of stochastic expres-
sion of genes is monitoring of production, degradation 
and functional status of separate biomolecules in real 
time in living cells [57]. Methods of mathematical 
(computed modeling) and experimental observations 
have showed significance of “noises” for heteroge-
neity/variability of phenotypes. The last one defines 
high evolutional potencies of population, high level 
of adaptation to environmental changes (3-rd type 
of populations according to Grant) [58], that is typical 
for population of TC.
For the possibly full analysis of molecular events, 
which are characterizing the phenomenon of TC het-
erogeneity, also should be mentioned the following. 
The various ways of generating the false proteins, 
which are not involved in processes of proliferation 
and cells apoptosis, but are important for alteration of 
‘social behavior’ of TC and their selective advantage 
over normal cells, are described. On the level of trans-
lation mistakes may occur cause of incorrect inclusion 
of amino acid, slippage of translation or absence 
of modification of tRNA, which causes the mistake 
of mRNA reading. Such mistakes are found one time 
on each 1000–10000 of translated codons and are 
referred to the heterogeneous characteristics of TC 
[59]. In tumor progression intensification of TC het-
erogeneity is possible in consequence of posttrans-
lational abnormalities (processing of predecessors, 
presentation and localization) of proteins, which are 
significant for preserving and multiplication of tumor 
population. The example may serve described long 
ago and observed with different frequency in differ-
ent TC decrease of expression on cellular membrane 
of antigens of the main complex of histocompatibility 
of the I class, which results in “invisibility” of such TC for 
recognition by effectors of specific cellular immunity 
[60]. Adaptation of tumors to peculiarities of metabo-
lism in microorganism may be reached by reprogram-
ming of metabolic ways of TC. Expression of some 
genes, which control key metabolic ways (glycolysis, 
lipogenesis and synthesis of nucleotides), is radically 
changing in different stages of tumor progression. 
Today 3 groups of genes are of particular importance: 
GLUT1, G6PD, TKTL1 and PGI/AMF (glycolysis); ACLY, 
ACC1 and FAS (lipogenesis); RRM2, p53R2 and TYMS 
(nucleotides synthesis), — changing of which may 
pay important contribution to growth of heterogeneity 
of TC population [61].
Summing above-stated, it may be noticed that 
phenotype of cells (including also TC) is finally de-
termined by combination of genetic program, impact 
of environment and accidental changes [3]. TC popu-
lations possess genetic, epigenetic and phenotypic 
heterogeneity, quantitative and qualitative parameters 
of which may dynamically change during tumor pro-
cess. Heterogeneity of tumors is connected with its 
more aggressive, metastatic behavior and resistance 
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(primary or acquired) to various antitumor impacts 
(chemotherapy, radial therapy, and immunotherapy) 
[62–64].
HETEROGENEITY OF METASTASES
The information on phenotypic and genotypic 
distinctions between cells of primary tumors and 
metastases, as well as on heterogeneity of meta-
static tumor lesions, is being accumulated. However, 
data are quite contradictory. In part of researches, 
in which characteristics of primary tumors and me-
tastases were compared, was found out quite close 
clonal relationship. In particular, such relationship was 
found out for primary and metastatic prostate tumors 
(independently of anatomic localization of metasta-
ses), that emphasizes natural monoclonality of these 
neoplasms. At the same time, heterogeneity both 
in primary tumors and in metastatic lesions at prostate 
cancer was discovered by the other researchers. The 
radical distinctions between primary and metastatic 
prostate tumors, as well as mammary gland, mani-
festing itself in loss of alleles, that indicates high de-
gree of genetic divergence, are discovered [65]. The 
comparison of consequences of primary lobular and 
metastatic tumors of mammary gland has discovered 
multiple mutations, inherent in metastases only [66]. 
It is considered that primary and metastatic tumors 
may develop as genetically different in cases, when 
metastatic dissemination occurs in the early stage 
of tumor progression. It is clear, that the clonal rela-
tionship between primary and metastatic populations 
of TC in malignant neoplasms of different histogenesis 
needs further study.
The question of clonal heterogeneity within metas-
tases is less studied. The complex network of meta-
static micromedia, complex interaction of TC, stroma 
cells, immune cells, noncellular matrix and dissolving 
factors are key players of progression and metastasis 
as well as heterogeneity of metastatic tumors. Again, 
stromal cells both of tumor and metastases co-evolve 
with TC, changing their geno- and phenotype with the 
aim of accommodation to the needs of their perma-
nently changing neoplastic neighbors [67].
Heterogeneity of metastases may be intermeta-
static and intrametastatic [68]. Intermetastatic het-
erogeneity is heterogeneity of various metastatic 
invasions of the same patient. Individual metastases 
are rather exception, than rule. It is common for one 
metastatic involvement to have 20 clonally genetic 
changes, which are not performed in other metastases 
of the same patient [69, 70]. Inasmuch they are clonal, 
these mutations were in stem cell of metastases, ex-
actly in cell, which was seized from the primary tumor 
and multiplied for formation of metastases. Founder 
cell for each metastasis is performed in anatomically 
different regions of primary tumors [69]. Heterogene-
ity mainly is limited with passenger gene mutations. 
Passenger mutations are not indifferent for the destiny 
of tumor. Having accumulated in enough quantity, they 
may retard or even stop its growth. In majority of re-
searches was showed that in malignant tumors driver 
genes Mut are performed inside tumor [71]. They con-
tain driver gene mutations (Mut-Driver gene) and are 
expressed aberrantly in such way that provides advan-
tage of selective growth (Epi-Driver gene). These data 
are coincided with idea that genetic changes, which 
are necessary for metastasis, were performed in cell 
before metastasis itself. The obtained data are also 
coincided with observation that in patients is observed 
response to targeted agents in all metastatic involve-
ments, but not only in small part [72]. Intrametastatic 
heterogeneity is heterogeneity of cells of the particular 
metastases. Each metastasis grows from one cell 
(or small group of cells) with set of founder mutations. 
With growth of metastatic tumor it acquires new muta-
tions with every cell division. Despite initial mutations 
are able to make metastasis sensitive to antitumor 
drugs, new mutations provide its drug resistance. 
Majority of initial metastases recur and terms of ori-
gin of new metastases are quite similar. This length 
by time may be explained by performance of mutations 
of resistance, which existed inside every metastasis 
before start of targeted therapy. Calculations show 
that any metastatic involvement of visualized size has 
thousands of cells, which already resistant to almost 
any drug [73–76]. One TC will be resistant to multitude 
of drugs, which influence different targets. Source 
of heterogeneity as well as call of resistance to the 
therapy is plasticity of tumor and immune cells [77]. 
Complex network of metastatic microenvironment, 
complex interaction of TC, stroma cells, noncellular 
matrix and dissolved factors are key players in pro-
gression and metastasis as well as heterogeneity 
of metastatic tumors. So, recurrence of metastasis 
is just question of time, is enough predictable on the 
basis of known frequency of mutations and speed 
of TC growth.
CONCLUSION
Thus, phenotypic, genetic and epigenetic hetero-
geneity are key elements in progression of tumor, its 
resistance to “hostile media” and therapeutic impact, 
inasmuch they provide population of cells with diver-
sity, resistance, opportunity of selection. Heterogene-
ity of tumor is active dynamic state, which is supported 
both by cellular and noncellular factors. New variants 
of cells, interacting between each other, help tumor 
to resist destructive influences. As any community, 
tumor is not just sum of components of its subpopula-
tions; it is interacting ecosystem, each feature of which 
may influence another. Biological features of “early” 
pre-invasive tumor are not similar to those of the same 
tumor, when it has reached stage of dissemination. 
Heterogeneity of tumor has many levels and molecular 
mechanisms (not finally discovered yet). All they to-
gether provide survival and diffusion (dissemination, 
colonization, and metastasis) of TC population. Every 
TC in organism of patient is unique by potential op-
portunity to undergo different changes and one TC, 
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which avoided effect of therapy, may potentially cause 
progression of disease.
Problem of clonal heterogeneity remains poorly 
studied. New approaches (including mathematical 
modeling) for characteristics of clonal heterogeneity 
of different types and subtypes of tumors in different 
stages of its development, as well as in conditions 
of different treatment impacts, are required. Neverthe-
less, our knowledge of TC heterogeneity has already 
found realization in diagnosis and treatment of cancer 
patients. For example, on the basis of detection of high 
heterogeneity of cells of gastric cancer and gastro-
esophageal cancer by expression of HER2/neu were 
elaborated principles of HER3-testing of these tumors, 
which differ from the same at human breast cancer.
Implementation of these principles let us essentially 
increase quality of diagnosis and choose optimal indi-
vidualized treatment tactics of patients with use of tar-
geted (anti-HER2/neu) drugs [78]. Another example 
may be recommendations on optimization of regimens 
of research of TC apoptosis for evaluation of effective-
ness of antitumor therapy [79], in particular, patients 
with human breast cancer [80] or metastatic kidney 
carcinoma [81], taking into account TC heterogeneity 
and asynchronicity of their death under the therapeutic 
effect. Majority of data on heterogeneity is obtained 
in result of tumor research, cells of which were se-
lected within the framework of organism. However, last 
researches have showed on the level of particular cell 
that in culture of cells of mammals after several divi-
sions originates wide spectrum of variability in local 
density of monolayer, in intracellular contacts, relative 
localization and quantity of free space on cell, in form 
and/or polarization of cells as well as their mobility. 
These parameters in combination constitute popula-
tion context of individual cells, in which each of them 
adapts own physiology. Such adaptation may be car-
ried out on the level of genes transcription, translation 
of particular proteins, regulation of cellular cycle, 
activity of proliferation, sensitivity of apoptosis, meta-
bolic properties. Listed characteristics define both 
behavior of individual cell in population and its influ-
ence on forming of population context. These complex 
and non-linear feedback mechanisms on many levels 
of cellular organization define phenotypic properties 
of particular cell in population, even when cells are not 
differentiating [82]. Above-stated summarized impor-
tant considerations related to intratumor heterogeneity 
during tumor development and put the problem of cel-
lular changeability and phenotypic heterogeneity not 
only in the center of today’s fundamental oncology, 
but also in the center of modern cell biology. New 
discoveries are only at the beginning of an era in which 
integration of rich data sets that probe the genome, 
epigenome and transcriptome will help us to unravel 
the intricate regulatory connections between hetero-
geneity and cancer. The ability to see heterogeneity 
processes inside the live cells and understand the 
causes of TC resistance is no longer a dream.
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